Mechanisms of resistance, novel biomarkers for patient selection, and beneficial combination therapies with PARP inhibitors and ICB therapy are among the foremost areas of research that must be further explored and characterized to optimize the use of PARP inhibitors in melanoma and limit AEs. This evidence concerns the gene PARP1 and melanoma.